Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age

aCentro de Pesquisa Clinica, Associacao Obras Sociais Irma Dulce and Oswaldo Cruz Foundation, Brazilian Ministry of Health, Salvador, Bahia, Brazil; bDepartment of Cancer Epidemiology, Center for Infection Research (CIRC), Moffitt Cancer Center, Tampa, Florida, USA; cCenter for Clinical Pharmacology, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium; dDepartment of Clinical Science, University of Bergen/Womens Clinic, Haukeland University Hospital, Bergen, Norway; eDepartment of Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; fFundaci on Centro de Investigaci on Cl inica CIC, Medell in, Colombia; gUniversity of Antwerp, Vaccine & Infectious Disease Institute, Centre for the Evaluation of Vaccination, Antwerp, Belgium; hLeuven University Vaccinology Center, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium; iMerck & Co. Inc., Kenilworth, New Jersey, USA